Intermittent Fasting Targets Osteocyte Neuropeptide Y to Relieve Osteoarthritis

Adv Sci (Weinh). 2024 Sep;11(34):e2400196. doi: 10.1002/advs.202400196. Epub 2024 Jul 8.

Abstract

Osteoarthritis is a highly prevalent progressive joint disease that still requires an optimal therapeutic approach. Intermittent fasting is an attractive dieting strategy for improving health. Here this study shows that intermittent fasting potently relieves medial meniscus (DMM)- or natural aging-induced osteoarthritic phenotypes. Osteocytes, the most abundant bone cells, secrete excess neuropeptide Y (NPY) during osteoarthritis, and this alteration can be altered by intermittent fasting. Both NPY and the NPY-abundant culture medium of osteocytes (OCY-CM) from osteoarthritic mice possess pro-inflammatory, pro-osteoclastic, and pro-neurite outgrowth effects, while OCY-CM from the intermittent fasting-treated osteoarthritic mice fails to induce significant stimulatory effects on inflammation, osteoclast formation, and neurite outgrowth. Depletion of osteocyte NPY significantly attenuates DMM-induced osteoarthritis and abolishes the benefits of intermittent fasting on osteoarthritis. This study suggests that osteocyte NPY is a key contributing factor in the pathogenesis of osteoarthritis and intermittent fasting represents a promising nonpharmacological antiosteoarthritis method by targeting osteocyte NPY.

Keywords: fasting; neuropeptide Y; osteoarthritis; therapeutics.

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Fasting*
  • Intermittent Fasting
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuropeptide Y* / metabolism
  • Osteoarthritis* / metabolism
  • Osteoarthritis* / therapy
  • Osteocytes* / metabolism

Substances

  • Neuropeptide Y